Entrepreneurship

CINM’s original intellectual property (IP) and technologies have contributed to economic development in the state. See some of our start-ups:

Startup

OstreaBio

Ostrea Bio develops therapies for the treatment of lysosomal storage diseases.

FACULTY FOUNDER:

Alexander Kabanov

YEAR FOUNDED:

2017

Startup

NeuroNano Pharma

NeuroNano Pharma has developed a series of formulation and delivery technologies that when used with current or newly discovered compounds it can 1) preserve biologics as they traverse the body, 2) improve the transport of polypeptides, proteins, hormones, enzymes and small molecules across cell membranes and tissue barriers, including the blood brain barrier, and 3) improve the release of drugs encapsulated in liposomes. NeuroNano technology has therapeutic applications in CNS disorders, metabolic diseases, cancer and ophthalmic disease.

FACULTY FOUNDER:

Alexander Kabanov

YEAR FOUNDED:

2017

Startup

Capio Biosciences

Capio Biosciences is focused on delivering high-value oncology diagnostics that can help inform patient care decisions and improve outcomes. Capio Biosciences is currently developing an advanced platform called CapioCyte™ for the capture of circulating tumor cells (CTCs) from whole blood. By utilizing a combination of biomimetic cell rolling and dendrimer-mediated multivalent cell capture, CapioCyte delivers significantly greater capture sensitivity than other platforms currently available.

FACULTY FOUNDER:

Andrew Wang

YEAR FOUNDED:

2015

Startup

DelAQUA Pharmaceuticals, Inc.

DelAQUA Pharmaceuticals, Inc., is a biopharmaceutical company whose proprietary technology enables it to create novel products based upon new chemical entities as well as enhance the performance of already-approved drugs that have major market shares. The Company’s platform technology uses non-PEG stealth approach that has been validated across dozens of very poorly soluble active pharmaceutical ingredients of different classes. The technology allows to greatly enhance the solubility and stability of drugs and drug candidates and to improve their efficacy and safety, thus widening their therapeutic window. delAQUA offers partnering and co-development of novel drug formulations with Pharmas including use of their proprietary compounds in delAQUA formats.

FACULTY FOUNDER:

Alexander Kabanov

YEAR FOUNDED:

2018